• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定义突变钙网织蛋白与 MPL 在 MPN 中的致病相互作用的要求。

Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.

机构信息

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.

出版信息

Blood. 2018 Feb 15;131(7):782-786. doi: 10.1182/blood-2017-08-800896. Epub 2017 Dec 29.

DOI:10.1182/blood-2017-08-800896
PMID:29288169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5814933/
Abstract

Mutations in calreticulin () are phenotypic drivers in the pathogenesis of myeloproliferative neoplasms. Mechanistic studies have demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive electrostatic charge of the mutant CALR C terminus is required for mutant CALR-mediated activation of JAK-STAT signaling. Here we demonstrate that although binding between mutant CALR and MPL is required for mutant CALR to transform hematopoietic cells; binding alone is insufficient for cytokine independent growth. We further show that the threshold of positive charge in the mutant CALR C terminus influences both binding of mutant CALR to MPL and activation of MPL signaling. We find that mutant CALR binds to the extracellular domain of MPL and that 3 tyrosine residues within the intracellular domain of MPL are required to activate signaling. With respect to mutant CALR function, we show that its lectin-dependent function is required for binding to MPL and for cytokine independent growth, whereas its chaperone and polypeptide-binding functionalities are dispensable. Together, our findings provide additional insights into the mechanism of the pathogenic mutant CALR-MPL interaction in myeloproliferative neoplasms.

摘要

钙网蛋白()突变是骨髓增殖性肿瘤发病机制中的表型驱动因素。机制研究表明,突变型 CALR 与血小板生成素受体 MPL 结合,突变型 CALR C 末端的正电荷对于突变型 CALR 介导的 JAK-STAT 信号转导激活是必需的。在这里,我们证明尽管突变型 CALR 与 MPL 之间的结合对于突变型 CALR 转化造血细胞是必需的;但结合本身不足以实现细胞因子非依赖性生长。我们进一步表明,突变型 CALR C 末端正电荷的阈值既影响突变型 CALR 与 MPL 的结合,也影响 MPL 信号的激活。我们发现突变型 CALR 与 MPL 的细胞外结构域结合,并且 MPL 细胞内结构域内的 3 个酪氨酸残基对于信号转导的激活是必需的。关于突变型 CALR 的功能,我们表明其凝集素依赖性功能对于与 MPL 的结合和细胞因子非依赖性生长是必需的,而其伴侣和多肽结合功能是可有可无的。总之,我们的发现为骨髓增殖性肿瘤中致病突变型 CALR-MPL 相互作用的机制提供了更多的见解。

相似文献

1
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.定义突变钙网织蛋白与 MPL 在 MPN 中的致病相互作用的要求。
Blood. 2018 Feb 15;131(7):782-786. doi: 10.1182/blood-2017-08-800896. Epub 2017 Dec 29.
2
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.突变型钙网蛋白的致癌转化需要其突变的C末端和血小板生成素受体。
Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.
3
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.CALR 突变型骨髓增殖性肿瘤中钙网织蛋白突变激活血小板生成素受体。
Blood. 2016 Mar 10;127(10):1307-16. doi: 10.1182/blood-2015-09-671172. Epub 2016 Jan 27.
4
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.骨髓增殖性肿瘤相关钙网蛋白突变体对血小板生成素受体的激活作用。
Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.
5
Mutant calreticulin in myeloproliferative neoplasms.骨髓增殖性肿瘤中的突变钙网织蛋白。
Blood. 2019 Dec 19;134(25):2242-2248. doi: 10.1182/blood.2019000622.
6
Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.随着钙网蛋白(CALR)突变型Ba/F3细胞在体内传代,内源性血小板生成素受体(MPL)上调,突出了MPL作为CALR介导转化所必需的细胞因子受体的作用。
Leuk Res. 2019 Jul;82:11-14. doi: 10.1016/j.leukres.2019.05.003. Epub 2019 May 9.
7
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.通过突变钙网蛋白导致骨髓增殖性肿瘤发生的机制。
Cancer Sci. 2020 Aug;111(8):2682-2688. doi: 10.1111/cas.14503. Epub 2020 Jun 27.
8
Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.骨髓增殖性肿瘤中突变分子伴侣介导细胞转化的新分子机制
Cancer Sci. 2017 Oct;108(10):1907-1912. doi: 10.1111/cas.13327. Epub 2017 Aug 8.
9
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.突变钙网蛋白的同源多聚化是 MPL 结合和激活的前提条件。
Leukemia. 2019 Jan;33(1):122-131. doi: 10.1038/s41375-018-0181-2. Epub 2018 Jun 26.
10
Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.苏木精与突变钙网蛋白结合,并破坏其与血小板生成素受体的异常相互作用。
Blood. 2021 Apr 8;137(14):1920-1931. doi: 10.1182/blood.2020006264.

引用本文的文献

1
Calreticulin-From the Endoplasmic Reticulum to the Plasma Membrane-Adventures of a Wandering Protein.钙网蛋白——从内质网到质膜——一种游走蛋白的历程
Cancers (Basel). 2025 Jan 17;17(2):288. doi: 10.3390/cancers17020288.
2
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.骨髓增殖性肿瘤中的突变型钙网蛋白:机制见解与治疗意义
Curr Hematol Malig Rep. 2025 Jan 8;20(1):4. doi: 10.1007/s11899-024-00749-4.
3
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity.“找我”和“吃我”信号:用于调节抗肿瘤免疫的吞噬过程的工具。
Cancer Commun (Lond). 2024 Jul;44(7):791-832. doi: 10.1002/cac2.12579. Epub 2024 Jun 23.
4
Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms.溶酶体降解靶向突变钙网织蛋白和骨髓增殖性肿瘤中的血小板生成素受体。
Blood Adv. 2024 Jul 9;8(13):3372-3387. doi: 10.1182/bloodadvances.2023011432.
5
In Silico Evaluation of Coding and Non-Coding nsSNPs in the Thrombopoietin Receptor () Proto-Oncogene: Assessing Their Influence on Protein Stability, Structure, and Function.血小板生成素受体()原癌基因中编码和非编码nsSNP的计算机模拟评估:评估它们对蛋白质稳定性、结构和功能的影响。
Curr Issues Mol Biol. 2023 Nov 23;45(12):9390-9412. doi: 10.3390/cimb45120589.
6
Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.致癌性 CALR 突变体 C 端介导双重结合到血小板生成素受体触发复合物二聚化和激活。
Nat Commun. 2023 Apr 5;14(1):1881. doi: 10.1038/s41467-023-37277-3.
7
Effects of calreticulin mutations on cell transformation and immunity.钙网织蛋白突变对细胞转化和免疫的影响。
J Cell Mol Med. 2023 Apr;27(8):1032-1044. doi: 10.1111/jcmm.17713. Epub 2023 Mar 13.
8
Biology and therapeutic targeting of molecular mechanisms in MPNs.骨髓增殖性肿瘤中分子机制的生物学和治疗靶向。
Blood. 2023 Apr 20;141(16):1922-1933. doi: 10.1182/blood.2022017416.
9
A marine sponge-derived lectin reveals hidden pathway for thrombopoietin receptor activation.一种海洋海绵来源的凝集素揭示了促血小板生成素受体激活的隐藏途径。
Nat Commun. 2022 Nov 25;13(1):7262. doi: 10.1038/s41467-022-34921-2.
10
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.分泌型突变钙网织蛋白作为骨髓增殖性肿瘤中的流氓细胞因子。
Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846.

本文引用的文献

1
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.钙网蛋白突变蛋白诱导巨核细胞信号传导,以转化造血细胞并经历加速降解和高尔基体介导的分泌。
J Hematol Oncol. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0.
2
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.突变型钙网蛋白的致癌转化需要其突变的C末端和血小板生成素受体。
Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.
3
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.CALR 突变型骨髓增殖性肿瘤中钙网织蛋白突变激活血小板生成素受体。
Blood. 2016 Mar 10;127(10):1307-16. doi: 10.1182/blood-2015-09-671172. Epub 2016 Jan 27.
4
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.骨髓增殖性肿瘤相关钙网蛋白突变体对血小板生成素受体的激活作用。
Blood. 2016 Mar 10;127(10):1325-35. doi: 10.1182/blood-2015-11-681932. Epub 2015 Dec 14.
5
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.钙网织蛋白突变小鼠诱导 MPL 依赖性血小板增多症,并常进展为骨髓纤维化。
Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.
6
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.伴有未突变 JAK2 的骨髓增殖性肿瘤中的体细胞 CALR 突变。
N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.
7
Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
8
Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).鉴定参与血小板生成素与核分布蛋白(人 NUDC)结合的血小板生成素受体细胞外结构域中的残基。
J Biol Chem. 2010 Aug 20;285(34):26697-709. doi: 10.1074/jbc.M110.120956. Epub 2010 Jun 7.
9
Identification by mutational analysis of amino acid residues essential in the chaperone function of calreticulin.通过突变分析鉴定钙网蛋白伴侣功能中必需的氨基酸残基。
J Biol Chem. 2006 Jan 27;281(4):2338-46. doi: 10.1074/jbc.M508302200. Epub 2005 Nov 16.
10
Delineation of the lectin site of the molecular chaperone calreticulin.分子伴侣钙网蛋白凝集素位点的描绘。
Cell Stress Chaperones. 2005 Autumn;10(3):242-51. doi: 10.1379/csc-126.1.